These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25857011)

  • 1. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
    Kawaida H; Fujii H
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
    [No Abstract]   [Full Text] [Related]  

  • 2. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
    Alemi F; Alseidi A; Scott Helton W; Rocha FG
    Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients.
    Shin SH; Kim SC; Song KB; Hwang DW; Lee JH; Park KM; Lee YJ
    Surgery; 2018 Sep; 164(3):432-442. PubMed ID: 29884479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
    Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
    Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the major prognostic factor in tumor-node-metastasis staging of pancreatic adenocarcinoma?
    Santi I; Brandt A; Hemminki K
    Ann Surg Oncol; 2011 Jan; 18(1):300-1. PubMed ID: 20589435
    [No Abstract]   [Full Text] [Related]  

  • 7. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to improve the outcome in locally advanced pancreatic cancer.
    Späth C; Nitsche U; Müller T; Michalski C; Erkan M; Kong B; Kleeff J
    Minerva Chir; 2015 Apr; 70(2):97-106. PubMed ID: 25658301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer.
    Gobbi PG; Bergonzi M; Comelli M; Villano L; Pozzoli D; Vanoli A; Dionigi P
    Cancer Epidemiol; 2013 Apr; 37(2):186-90. PubMed ID: 23369450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pancreatic cancer- a curable disease].
    Limani P; Samaras P; Lesurtel M; Graf R; DeOliveira ML; Petrowsky H; Clavien PA
    Praxis (Bern 1994); 2015 Apr; 104(9):453-60. PubMed ID: 25900693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
    Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
    Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenges of improving survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Shukla PJ
    Ann Surg; 2011 Aug; 254(2):385-6; author reply 386. PubMed ID: 21677560
    [No Abstract]   [Full Text] [Related]  

  • 14. Irreversible electroporation: a novel therapy for stage III pancreatic cancer.
    Weiss MJ; Wolfgang CL
    Adv Surg; 2014; 48():253-8. PubMed ID: 25293620
    [No Abstract]   [Full Text] [Related]  

  • 15. Accuracy of Clinical Staging in Early-Stage Pancreatic Ductal Adenocarcinoma.
    Perrotta G; Mohamed G; Larson BK; Osipov A; Ferrone CR; Lo SK; Gaddam S
    JAMA; 2024 Oct; 332(13):1108-1110. PubMed ID: 39235802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for subtypes of pancreatic ductal adenocarcinoma.
    Venkatesan P
    Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
    Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pancreatic cancer multidisciplinary clinic: insights and outcomes.
    Schiffman SC; Abberbock S; Winters S; Valko C; Steve J; Zureikat AH; Zeh HJ; Hogg ME
    J Surg Res; 2016 May; 202(2):246-52. PubMed ID: 27229097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
    Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
    Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
    Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
    Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.